Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 5/2013

01-05-2013 | Original Article

Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience

Author: Escarlata López Ramírez

Published in: Supportive Care in Cancer | Issue 5/2013

Login to get access

Abstract

Purpose

This study aims to evaluate the utility of a new technology, Lidocaine 5 % patch (L5%P), for providing analgesia without other sensory deficit in cancer patients with focal neuropathic pain (NP) related or not with cancer.

Methods

During the period February 2011 to July 2011, 83 patients were seen for the first time in our department and L5%P were prescribed to 15 of those patients (18.07 %). Information recorded in relation to the L5%P included the following: (a) Nature of NP, (b) medications tested, (c) drug combinations, (d) L5%P therapy duration, (e) efficacy, and (f) undesirable effects.

Results

Forty percent of the patients (n = 6) in our series had NP related to their cancer and 60 % (n = 9), chronic NP not related to their cancer diagnosis, but all referred to our Radiotherapy and Oncology Department for radiotherapy. The analgesic effect of the L5%P was potent in eight cases (53.33 %) and partial in four cases (26.66 %). This represents 79.99 % efficacy in selected patients. There were no serious adverse events reported in any of the patients.

Conclusion

The results indicate that there are patients with NP within a cancer setting who are suitable for treatment and successfully managed with topical L5%P, alone or in combination with other drugs.
Literature
1.
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pain: redefinition and grading system for clinical and research purposes. Neurology 70:1630–1635PubMedCrossRef
2.
Finnerup NB, Sindrup SH, Jensen TS (2010) Recent advances in pharmacological treatment of neuropathic pain. Med Rep 2:52–54
3.
Cleeland CS, Farrar JT, Hausheer FH (2010) Assessment of cancer-related neuropathy and neuropathic pain. Oncologist 15(suppl 2):13–18PubMedCrossRef
4.
Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. Pain 82:263–274PubMedCrossRef
5.
Fleming JA, O’Connor BD (2009) Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 15:381–388
6.
Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A (2005) A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manag 29:224–237CrossRef
7.
Lema MJ, Foley KM, Hausherr FH (2010) Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain. Oncologist 15(suppl 2):3–8PubMedCrossRef
8.
9.
10.
Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118:289–305PubMedCrossRef
11.
Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS (2007) Pharmacologic management of neuropathic pain: evidence based recommendations. Pain 132:237–251PubMedCrossRef
12.
Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M (2009) 5 % Lidocaine medicated plaster versus pregabalin in postherpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 25:1663–1676PubMedCrossRef
13.
Pérez C, Gálvez R, Huelbes S, Insausti J, Boyhassira D, Díaz S et al (2007) Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 5:66PubMedCrossRef
14.
Persaud N, Strichartz GR (2002) Micromolar lidocaine selectively blocks propagating ectopic impulses at a distance from their site of origin. Pain 99:333–340PubMedCrossRef
15.
Chow E, Wu JS, Hoskin P et al (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64:275–280PubMedCrossRef
16.
Brennan F, Carr DB, Cousins M (2007) Pain management: a fundamental human right. Anesth Analg 105:205–221PubMedCrossRef
17.
Hausherr FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncolo 33:15–49CrossRef
18.
Jost L, Roila F (2009) ESMO guidelines working group. Management of cancer pain: ESMO clinical recommendations. Ann Oncol 20(suppl 4):170–173PubMed
19.
20.
Campbell BJ, Rowbotham M, Davies PS, Jacob P III, Benowitz NL (2002) Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 91:1343–1350PubMedCrossRef
21.
Sinnot C (2002) Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care. J Pain Symptom Manag 23:270–272CrossRef
22.
Meier T, Wasner G, Faust M et al (2003) Efficacy of lidocaine patch 5 % in the treatment of focal peripheral neuropathic pain syndromes: A randomized double-blind, placebo-controlled study. Pain 106:151–158PubMedCrossRef
23.
Galer BS (2002) Effectiveness and safety of lidocaine patch 5 %. J Fam Pract 51:867–868PubMed
24.
Nalamachu S, Crockett RS, Mathur D (2006) Lidocaine patch 5 for carpal tunnel syndrome: how it compares with injections: a pilot study. J Fam Pract 55:209–214PubMed
25.
Kehlet H, Jensen TS, Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367:1618–1625PubMedCrossRef
26.
Cheville AL, Sloan JA, Northfelt DW et al (2009) Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (NO1CB). Support Care Cancer 17:451–460PubMedCrossRef
27.
Lin PL, Fan SZ, Huang CH et al (2008) Analgesic effect of lidocaine patch 5 % in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med 33:320–325PubMed
28.
Mackley CL, Marks JG Jr, Anderson BE (2003) Delayed-type hypersensitivity to lidocaine. Arch Dermatol 139:343–346PubMedCrossRef
Metadata
Title
Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience
Author
Escarlata López Ramírez
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 5/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1670-x

Other articles of this Issue 5/2013

Supportive Care in Cancer 5/2013 Go to the issue

Original Article

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

Original Article

Evaluating a knowledge exchange intervention in cancer survivorship care: a workshop to foster implementation of Online Support Groups

Short Communication

Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study

Original Article

Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV

Original Article

Predicting quality of life after breast cancer surgery using ANN-based models: performance comparison with MR

Short Communication

Validation of the Chinese version of the Resilience Scale and its cutoff score for detecting low resilience in Chinese cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits